Reginster J Y, Rabenda V, Neuprez A
WHO Collaborating Center for Public Health Aspects of Rheumatic Diseases, University of Liège, Liège, Belgium.
Bone. 2006 Apr;38(4 Suppl 1):S2-6. doi: 10.1016/j.bone.2006.01.150. Epub 2006 Mar 7.
Adherence to treatment among patients with chronic diseases is currently suboptimal. Poor adherence leads to reduced clinical benefit, a raised incidence of secondary complications and therefore increased healthcare costs. For patients with osteoporosis, long-term adherence to therapy is further complicated by the asymptomatic nature of the disease and the lack of options for patient self-monitoring. Bone densitometry and biochemical markers of bone turnover are assessments that could be used by physicians to provide feedback to patients on the effectiveness of medication. However, these feedback systems are costly and not readily available. Oral bisphosphonates are currently the first-line therapy for postmenopausal osteoporosis. However, they are associated with stringent dosing procedures, and some patients may experience upper gastrointestinal side-effects following administration. Alarmingly, approximately 50% of patients discontinue daily bisphosphonate therapy within 1 year, which negatively impacts upon treatment outcomes, leading to a reduced antifracture effect. Thus, there is a need for an effective therapy that enhances patient adherence. The impact of reducing bisphosphonate dosing frequency on therapeutic adherence has been documented in several studies. Data have shown that, although weekly dosing improves adherence compared with daily administration, levels are still suboptimal. Results from two recent studies that have assessed patient preference for a once-monthly compared with a weekly dosing schedule have demonstrated that patients prefer a monthly regimen (67-71%). Their reasons for preferring once-monthly dosing were that it would fit better with their lifestyle (49-77%) and would be more convenient (75%). A novel once-monthly bisphosphonate regimen, such as the ibandronate regimen, may therefore help patients to follow dosing guidelines and encourage them to stay on therapy longer, thereby improving overall therapy effectiveness.
目前,慢性病患者的治疗依从性欠佳。依从性差会导致临床获益减少、继发并发症的发生率升高,进而增加医疗成本。对于骨质疏松症患者而言,由于该疾病无症状的特性以及患者缺乏自我监测的手段,长期坚持治疗变得更加复杂。骨密度测定和骨转换生化标志物是医生可用于向患者反馈药物疗效的评估方法。然而,这些反馈系统成本高昂且不易获得。口服双膦酸盐类药物目前是绝经后骨质疏松症的一线治疗药物。然而,它们的给药程序严格,一些患者在服药后可能会出现上消化道副作用。令人担忧的是,约50%的患者在1年内停止每日双膦酸盐治疗,这对治疗结果产生负面影响,导致抗骨折效果降低。因此,需要一种能提高患者依从性的有效治疗方法。多项研究记录了降低双膦酸盐给药频率对治疗依从性的影响。数据表明,尽管与每日给药相比,每周给药可提高依从性,但依从性水平仍不理想。最近两项评估患者对每月一次给药方案与每周一次给药方案偏好的研究结果表明,患者更喜欢每月给药方案(67 - 71%)。他们更喜欢每月给药一次的原因是,这更符合他们的生活方式(49 - 77%)且更方便(75%)。因此,一种新型的每月一次双膦酸盐给药方案,如伊班膦酸钠给药方案,可能有助于患者遵循给药指南,并鼓励他们坚持治疗更长时间,从而提高整体治疗效果。